Israel - English - Ministry of Health

novo nordisk ltd., israel - turoctocog alfa - powder and solvent for solution for injection - turoctocog alfa 2000 iu / 4 ml - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).novoeight can be used for all age groups.

Israel - English - Ministry of Health

novo nordisk ltd, israel - turoctocog alfa - powder and solvent for solution for injection - turoctocog alfa 250 iu / 4 ml - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).novoeight can be used for all age groups.

Israel - English - Ministry of Health

novo nordisk ltd, israel - turoctocog alfa - powder and solvent for solution for injection - turoctocog alfa 3000 iu / 4 ml - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).novoeight can be used for all age groups.

Israel - English - Ministry of Health

novo nordisk ltd., israel - turoctocog alfa - powder and solvent for solution for injection - turoctocog alfa 500 iu / 4 ml - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).novoeight can be used for all age groups.

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - general hospital - the administration set is to be used for injection (administration) of novo nordisk factor products and contains: 1 sterile infusion set (tubing and butterfly with needle protection), 2 sterile alcohol swabs, 2 sterile gauze pads and 2 sterile plasters

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - general hospital - intended to deliver novo nordisk insulin products packaged in a 3 ml penfill® cartridge and used together with novofine® needles.

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - liraglutide 6 mg/ml;   - solution for injection - 6 mg/ml - active: liraglutide 6 mg/ml   excipient: dibasic sodium phosphate dihydrate hydrochloric acid phenol propylene glycol sodium hydroxide water for injection - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of · 30 kg/m2 or greater (obese) or · 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea. treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - general hospital - novo pen echo® is a re-usable mechanically driven pen injector designed for single-patient use by diabetics for the self-injection of a desired dose of insulin a dose setting range of 0.5 to 30 units in one half (1/2) unit increments.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart -

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart -